CHOLANGIOCARCINOMA

This study tests whether a daily pill called ivosidenib can help keep bile duct cancer from returning after surgery and chemotherapy. It is for people with a specific gene change (IDH1 mutation). About 40 adults will take the drug for one year, and researchers will track how many…

This study tests whether taking spirulina tablets before and after liver surgery can help protect the liver and speed up recovery. Thirty adults with bile duct cancer will take either spirulina or a placebo for three weeks before and after their operation. Researchers will measur…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This study tests a new drug called LY4337713, which delivers radiation directly to cancer cells that have a specific protein (FAP). It is for adults with advanced or spread-out cancers like pancreatic, breast, ovarian, colorectal, esophageal, stomach, or bile duct cancer. The mai…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. The study includes people with ovarian, endomet…

This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus immunotherapy (anti-PD-1/PD-L1 antibodies) as a first treatment. The goal is to see if this combination is …

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (like lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink or control the cancer…

This study tests a new approach for people with a type of bile duct cancer that is difficult to remove with surgery. Participants receive a combination of targeted radiation, immunotherapy (tislelizumab), and chemotherapy before any surgery. The goal is to shrink the tumor enough…

This study tests a drug called tivozanib for people with bile duct cancer that can't be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink or slow the cancer. About 31 adults will take tivozanib pi…

This study tests a combination of four drugs (gemcitabine, cisplatin, zimberelimab, and quemliclustat) as a first treatment for people with advanced bile duct cancer that has not spread beyond the bile ducts. The goal is to see if this mix can slow cancer growth and help people l…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard liver-directed chemotherapy can help people with certain cancers that have spread to the liver. About 70 adults with colorectal cancer, bile duct cancer, or adrenal cancer that is mainly in the liver w…

This study is tracking how well the targeted drug ivosidenib works for people with advanced bile duct cancer that has a specific IDH1 mutation. About 100 adults in Germany who have already tried at least one other cancer treatment will take ivosidenib as prescribed by their docto…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (cisplatin and gemcitabine) before and after surgery can improve long-term outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. About 24 adults wit…

This study tests a new combination of two chemotherapy drugs (trifluridine/tipiracil pills plus oxaliplatin by IV) in people with advanced or metastatic biliary tract cancer whose first treatment stopped working or didn't help. The goal is to see if this combo controls the cancer…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests whether using a special surgical glue (Glubran® 2) during pancreas surgery can prevent dangerous fluid leaks. About 194 adults with pancreatic or related cancers who need surgery will be randomly assigned to receive the glue or standard care. The main goal is to …

This study tests a new treatment approach for people with advanced bile duct cancer that has spread. It combines a special type of radiation (PULSAR) with two immunotherapy drugs and chemotherapy. The goal is to see if this combination is safe and effective. About 60 adults aged …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This study tests a daily pill called ivosidenib in adults with advanced bile duct cancer that has a specific gene change (IDH1 mutation). Participants must have already tried at least one other cancer treatment. The goal is to see if the drug is safe and helps control the cancer.…

This study tests a new drug called BOLD-100 combined with standard chemotherapy (FOLFOX) in people with advanced solid tumors like colorectal, pancreatic, gastric, and bile duct cancers. The goal is to see if the combination is safe and can shrink or slow tumor growth. About 220 …

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This study is for people with bile duct cancer that cannot be removed by surgery. It combines three treatments: radiation beads (Y-90), an immunotherapy drug (durvalumab), and two chemotherapy drugs (gemcitabine and cisplatin). The goal is to see if this mix can slow cancer growt…

This study tests whether combining two drugs, afatinib and pemigatinib, is safe and can shrink tumors in people with advanced solid cancers that have certain genetic changes (FGFR alterations). About 70 adults whose standard treatments have stopped working will take part. The mai…

This study tests a new combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change called a KRAS mutation. The cancer must have worsened after at least one round of standard chemotherapy. The goal is to see if the c…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can better detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. About 120 adults with newly diagnosed, potentially curable cancer will receive the new scan. If it proves mo…

This study is testing a new type of PET scan that uses a special tracer to find a protein called Trop2 on cancer cells. The goal is to see if this scan can detect and monitor many types of solid tumors more accurately than current methods. About 400 adults with or suspected of ha…

This study is testing a new imaging agent called 18F-T2, which targets a protein (CAIX) found on many solid tumors. About 200 adults with cancers like kidney, bladder, colorectal, or lung cancer will receive a PET/CT scan using this agent. The goal is to see if it can find tumors…

This study aims to develop a blood test that uses tiny particles called exosomes and machine learning to help doctors accurately tell apart two common types of liver cancer—hepatocellular carcinoma and cholangiocarcinoma—before surgery. Researchers will collect blood samples from…

This study is testing a new way to diagnose cholangiocarcinoma (bile duct cancer) by analyzing proteins in bile fluid instead of taking a tissue sample. Researchers will compare the accuracy of this bile test with standard biopsy methods. The study involves 200 adults with bile d…

This study aims to create a blood test that can detect several types of gastrointestinal cancers—like liver, pancreatic, and colon cancer—at an early stage. Current screening methods are often invasive or not sensitive enough. The test looks for tiny molecules called miRNAs in th…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer on PET scans. About 110 adults with liver tumors will receive the tracer before surgery or transplant, and the results will be compared with standard scans and tissue analysis. T…

This study looks back at 1,200 patients who had a breathing tube placed during surgery to see how many developed voice box injuries like hoarseness or sore throat. Researchers will review medical records and follow up by phone to find out what factors increase the risk and how lo…

This study looks at how olutasidenib, a drug for certain cancers with an IDH1 mutation, changes the way the body processes other medications. Researchers will give participants a mix of test drugs before and during olutasidenib treatment to measure differences in drug levels. The…

This pilot study aims to see if taking a blood sample from the vein that drains directly from a liver or pancreatic tumor can detect more cancer DNA than a standard blood draw from the arm. Fifteen adults scheduled for a tumor biopsy will provide both types of blood samples. The …

This study looks at what causes biliary tree cancers by examining environmental, viral, and genetic factors. Researchers will study 1500 people, including patients and healthy volunteers, to find markers that predict cancer development and treatment response. The goal is to bette…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at how often a specific gene change (BAP1 mutation) is found in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. T…

This study creates a collection of blood, urine, stool, and other samples from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis. The samples and health data will be used by researchers to better understand thes…

This study collects tumor and nearby normal tissue samples from people already scheduled for surgery or biopsy at the NIH Clinical Center. Up to 1,800 adults and children (age 2+) with solid tumors can join. The samples are used to identify new molecular targets for future cancer…

This study is for people with advanced biliary tract cancer (a type of bile duct cancer) who are scheduled to receive a combination of two drugs, lenvatinib and pembrolizumab. Researchers want to find genetic markers in blood and tumor samples that might predict how well a person…

This study is collecting tissue and fluid samples from 160 people with suspected liver, bile duct, or pancreatic cancers. Researchers will analyze these samples to understand the cancers better and test new imaging and robotic tools for earlier, more accurate diagnosis. The goal …

This research study collects bile, bile duct brushings, and medical information from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers. The goal is to learn more about changes in the liver that may lead to disease. No treatments or drugs are tested.